Anticoagulation Management in Atrial Fibrillation with Bioprosthetic Valves

Introduction to Anticoagulation Therapy

• The American Heart Association, American College of Cardiology, and Heart Rhythm Society recommend the use of direct oral anticoagulants (DOACs) like apixaban in patients with atrial fibrillation and bioprosthetic valves, as supported by the 2019 guidelines 1, 2

Transitioning from Warfarin to Apixaban

• The first dose of apixaban should be administered when the INR is below 2.0 after stopping warfarin in patients with atrial fibrillation and bioprosthetic valve 1, 2
• The transition from warfarin to apixaban requires careful consideration to maintain effective anticoagulation while minimizing bleeding risk, particularly in patients with atrial fibrillation and bioprosthetic valves 1, 2

Dosing and Administration

• Standard dosing of apixaban is 5 mg twice daily, with reduced dosing of 2.5 mg twice daily if the patient meets at least two of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 1, 2
• Renal function should be assessed before initiating apixaban, as dosing is affected by creatinine clearance 1, 2

Monitoring and Follow-up

• Check INR daily or every other day after stopping warfarin until it falls below 2.0, and once apixaban is started, no routine coagulation monitoring is required 1, 2
• Regular follow-up is recommended to assess for bleeding complications or thromboembolic events 1, 2

Special Considerations

• Patients with mechanical valves require warfarin, and DOACs including apixaban are contraindicated, as stated by the guidelines from Circulation in 2008 3
• The evidence supporting DOACs in patients with bioprosthetic valves is growing but still limited compared to the broader atrial fibrillation population 1, 2